Home » Newsletters » BioWorld Science

BioWorld Science

June 29, 2009

View Archived Issues

New data on saxagliptin, preregistered for type 2 diabetes, released at ADA congress

ASCO snapshots: data from phase II trials of potential treatments for lung cancer disclosed

Snapshots: potential new treatments for melanoma presented at ASCO

First phase III study of bupropion/naltrexone shows benefits besides weight loss in obesity

Novel glycogen phosphorylase inhibitor designed at GlaxoSmithKline

Afresa data show efficacy and pulmonary function safety in diabetes patients

Jazz Pharmaceuticals puts three drugs on hold, will continue development of sodium oxybate

Janssen launches its long-acting antipsychotic drug Risperdal Consta in Japan

Bionomics commences phase I trial of anxiety drug candidate, BNC-210

Addex initiates phase I trial for mGluR positive allosteric modulator ADX-71149

Orchid Chemicals & Pharmaceuticals discovers pSTAT3/IL-6 inhibitors for cancer therapy

Neuraxon presents dual nNOS and NE reuptake inhibitors as analgesics

Nucynta immediate-release tablets launched in the U.S. for acute pain

Oxigene commences phase II Zybrestat trial for ophthalmology

Cytos reports biochemical findings from phase IIa hypertension vaccine trial

Osiris reports phase II clinical trial results of Prochymal in COPD

E.U. approves Novartis' once-yearly Aclasta for steroid-induced osteoporosis

CHMP issues positive opinion regarding BMS and AstraZeneca's MAA for Onglyza

Phase I study reveals tolerability, gene expression changes with ABR-215757 in SLE

Effect of RDEA-594 on renal transporters evaluated

Pasireotide snapshots: Recent preclinical and clinical studies

Boehringer receives positive recommendation from the EMEA for Mirapexin

FDA issues preliminary review letter regarding Acura Pharmaceuticals' NDA for Acurox

Cerulean signs worldwide license agreement with Arrowhead for Cyclosert and IT-101

European CHMP recommends marketing authorization for UCB's Cimzia in RA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...